Paper Details

  1. Home
  2. Paper Details

An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.

Author: BouabdallahKrimo, CartronGuillaume, FabianiBettina, HouotRoch, Le GouillSteven, MorschhauserFranck, MénardCédric, SallesGilles, TarteKarin, ThieblemontCatherine, TillyHerve

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Lenalidomide combined with obinutuzumab is a well-tolerated and effective treatment for relapsed or refractory follicular lymphoma (FL) after rituximab-containing therapy. The recommended dose of lenalidomide is 20mg due to a risk of grade 3/4 neutropenia from cycle 2.
Paper Details　
Original Abstract of the Article :
Obinutuzumab is a type II anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity better than rituximab. Given promising results with lenalidomide and rituximab, this phase 1b study assessed the safety and efficacy of lenalidomide combined with obinutuzumab (GALEN). Pati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225348/

データ提供：米国国立医学図書館（NLM）

A New Hope for Follicular Lymphoma: Obinutuzumab and Lenalidomide

This research focuses on follicular lymphoma, a type of cancer that affects the lymphatic system. The study is like a search for a rare oasis in a vast and unforgiving desert, seeking to find new ways to fight this disease. It explores the potential of combining two promising drugs, obinutuzumab and lenalidomide, in treating relapsed or refractory follicular lymphoma. The researchers conducted a phase 1b clinical trial, meticulously evaluating the safety and efficacy of this combination therapy.

Positive Results: A Promising Combination Therapy

The study found that the combination of obinutuzumab and lenalidomide was well tolerated and showed promising efficacy in patients with relapsed or refractory follicular lymphoma. This is like discovering a hidden spring of hope in the desert, offering new possibilities for treatment. The study provides valuable data for future research and clinical applications.

Hope on the Horizon for Follicular Lymphoma Patients

This research offers a ray of hope for patients struggling with relapsed or refractory follicular lymphoma. The study suggests that the combination of obinutuzumab and lenalidomide could be a valuable treatment option. It's like finding a new path through the desert, offering a brighter and more hopeful future for those affected by this disease.

Dr. Camel's Conclusion

This research is a testament to the ongoing quest for innovative treatments for cancer. The combination of obinutuzumab and lenalidomide offers a promising approach to treating relapsed or refractory follicular lymphoma. It's like uncovering a hidden gem in the desert, offering a glimmer of hope for those seeking effective treatment options.

Date :
  1. Date Completed 2019-07-23
  2. Date Revised 2021-02-02
Further Info :

Pubmed ID

30068505

DOI: Digital Object Identifier

PMC6225348

Related Literature

Article Analysis
・Effects of obinutuzumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.